Mylan's EpiPen Nightmare Not Over Yet, But Will Congress Just Write?

Unless Republicans are convinced the market can't fix the problem, Mylan officials may only get congressional letters on the EpiPen price increase.

Capitol House

Mylan NV's defense of its price increases for EpiPen do not seem to have assuaged a number of members of Congress, but the real question may be how many Republicans believe the company should be the focus of their ire.

The chorus of Democrats calling for congressional scrutiny of Mylan's pricing of EpiPen (epinephrine), as well as its decision to...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Review Pathways

More from Pathways & Standards